Showing results (191-200 of 333) with videos related to

Sort By:
Pageof 34
Molecular Cancer|June 3, 2014
Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancerYosuke Togashi, Hiroki Sakamoto, Hidetoshi Hayashi, et al.
Cancer Letters|December 3, 2014
Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancerYosuke Togashi, Akihiro Kogita, Hiroki Sakamoto, et al.
Scientific Reports|May 5, 2021
Periplocin and cardiac glycosides suppress the unfolded protein responseMuneshige Tokugawa, Yasumichi Inoue, Kan'ichiro Ishiuchi, et al.
Scientific Reports|July 2, 2025
Pharmacologic inhibition of BMI1 exerts antitumor effects against MYCN-amplified neuroblastoma, with activation of the p53 pathwayMasahiro Hirayama, Eri Yamada, Hiromasa Aoki, et al.
Future Oncology (London, England)|October 7, 2025
IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancerTaofeek K Owonikoko, Lauren Byers, Ying Cheng, et al.
The Journal of Clinical Investigation|March 10, 2026
Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLCKohsuke Isomoto, Koji Haratani, Takahiro Tsujikawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 31, 2022
Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infectionSatoru Hagiwara, Naoshi Nishida, Hiroshi Ida, et al.
International Immunopharmacology|February 15, 2003
Multiple mechanisms involved in the inhibition of proinflammatory cytokine production from human monocytes by N-(p-coumaroyl)serotonin and its derivativesTakemasa Takii, Sachiko Kawashima, Taku Chiba, et al.
International Journal of Oncology|October 18, 2016
MEK inhibitors against MET-amplified non-small cell lung cancerMasato Chiba, Yosuke Togashi, Shuta Tomida, et al.
Investigational New Drugs|February 22, 2019
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutationsMakoto Nishio, Haruyasu Murakami, Yuichiro Ohe, et al.
Pageof 34